Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ4 | P56696 | 3/20 | 0.50 |
| ▸ | KCNQ5 | Q9NR82 | 3/20 | 0.50 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.49 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22411949 | 0.89 | KCNQ4 (0.47) | KCNQ4KCNQ5CYP17A1AKT1AAK1 | |
| SCHEMBL31172075 | 0.89 | KCNQ4 (0.47) | KCNQ4KCNQ5CYP17A1AKT1AAK1 | |
| SCHEMBL28207323 | 0.87 | CYP17A1 (0.50) | KCNQ4KCNQ5CYP17A1AAK1RXFP1 | |
| SCHEMBL29468015 | 0.86 | CYP17A1 (0.49) | KCNQ4KCNQ5CYP17A1AAK1RXFP1 | |
| SCHEMBL16245955 | 0.85 | CYP17A1 (0.48) | KCNQ4KCNQ5CYP17A1RXFP1P2RX3 | |
| SCHEMBL6676620 | 0.84 | SMN1; SMN2 (0.47) | KCNQ4KCNQ5CYP17A1AKT1POLB | |
| SCHEMBL27772977 | 0.84 | CYP17A1 (0.47) | KCNQ4KCNQ5CYP17A1AAK1RXFP1 | |
| SCHEMBL16246161 | 0.84 | CYP17A1 (0.47) | KCNQ4KCNQ5CYP17A1AKT1RXFP1 | |
| SCHEMBL22941806 | 0.83 | KCNQ4 (0.45) | KCNQ4KCNQ5CYP17A1AKT1 | |
| SCHEMBL27403362 | 0.83 | KCNQ4 (0.47) | KCNQ4KCNQ5CYP17A1AKT1AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4006033-A1 | ADENOSINE RECEPTOR ANTAGONIST | Xiamen Biotime Biotechnology Co., Ltd. (CN) | 2022-06-01 | — | — | EP | disclosed |
| WO-2021018173-A1 | ADENOSINE RECEPTOR ANTAGONIST | 杭州阿诺生物医药科技有限公司 | 2021-02-04 | — | — | WO | disclosed |
| CN-109563043-A | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | 葛兰素史密斯克莱知识产权发展有限公司 | 2019-04-02 | — | — | CN | disclosed |
| EP-1651214-B1 | BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | WARNER LAMBERT CO (US) | 2009-09-16 | — | — | EP | disclosed |
| US-7488748-B2 | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-10 | — | — | US | disclosed |
| US-7273877-B2 | 5-substituted-4-[(substituted phenyl) amino]-2-pyridone derivatives | WARNER-LAMBERT COMPANY, LLC (US) | 2007-09-25 | — | — | US | disclosed |
| US-7160915-B2 | N-methyl-substituted benzamidazoles | WARNER-LAMBERT COMPANY, LLC (US) | 2007-01-09 | — | — | US | disclosed |
| US-20060247225-A1 | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2006-11-02 | — | — | US | disclosed |
| US-7078438-B2 | N-(4 substituted phenyl)-anthranilic acid hydroxamate esters | WARNER-LAMBERT COMPANY (US) | 2006-07-18 | — | — | US | disclosed |
| EP-1651214-A2 | BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2006-05-03 | — | — | EP | disclosed |
| US-20050026970-A1 | N-methyl-substituted benzamidazoles | WARNER-LAMBERT COMPANY | 2005-02-03 | — | — | US | disclosed |
| WO-2005007616-A1 | DIPHENYLAMINO KETONE DERIVATIVES AS MEK INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2005-01-27 | — | — | WO | disclosed |
| EP-1467965-A1 | N-(4-SUBSTITUTED PHENYL)-ANTHRANILIC ACID HYDROXAMATE ESTERS | Warner-Lambert Company LLC (US) | 2004-10-20 | — | — | EP | disclosed |
| EP-1467968-A1 | N-(4-SUBSTITUTED PHENYL)-ANTHRANILIC ACID HYDROXAMATE ESTERS | Warner-Lambert Company LLC (US) | 2004-10-20 | — | — | EP | disclosed |
| WO-2004067510-A1 | 3,6-DISUBSTITUTED AZABICYCLO HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2004-08-12 | — | — | WO | disclosed |
| US-6770778-B2 | MAP KINASE INHIBITORS; ANTICARCINOGENIC AGENTS; RESTENOSIS, PSORIASIS, AND ATHEROSCLEROSIS TREATMENT; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS | PFIZER INC | 2004-08-03 | — | — | US | disclosed |
| US-20040006245-A1 | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters | REWCASTLE GORDON WILLIAM (NZ) | 2004-01-08 | — | — | US | disclosed |
| US-20030232889-A1 | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters | WARNET-LAMBERT COMPANY LLC | 2003-12-18 | — | — | US | disclosed |
| WO-2003062191-A1 | N-(4-SUBSTITUTED PHENYL)-ANTHRANILIC ACID HYDROXAMATE ESTERS | WARNER-LAMBERT COMPANY LLC (US) | 2003-07-31 | — | — | WO | disclosed |
| WO-2003062189-A1 | N-(4-SUBSTITUTED PHENYL)-ANTHRANILIC ACID HYDROXAMATE ESTERS | WARNER-LAMBERT COMPANY LLC (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232889-A1 | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters | AADAC, EGLN3, HCAR2 | KCNQ4 2198/4885KCNQ5 2305/4885CYP17A1 326/4885 |
| US-20050026970-A1 | N-methyl-substituted benzamidazoles | CYP3A5, CYP3A7, UGT2B7 | KCNQ4 1313/4885KCNQ5 733/4885CYP17A1 310/4885 |
| US-20060247225-A1 | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | KCNQ4 1254/4885KCNQ5 785/4885CYP17A1 1199/4885 |
| US-20040006245-A1 | N-(4-substituted phenyl)-anthranilic acid hydroxamate esters | HCAR2, EGLN3, AADAC | KCNQ4 2217/4885KCNQ5 2331/4885CYP17A1 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.